Importing human serum samples from clinical trial participants requires more than identifying the material as blood or a blood derivative. FDA jurisdiction generally depends on intended use, while infectious-agent controls, tariff classification, transportation requirements, and entry documentation remain separate compliance considerations that importers and customs brokers must address.
When Human Serum Samples Fall Outside FDA Oversight
Intended Use Determines the FDA Filing Approach
Human serum, plasma, and blood specimens imported solely for clinical laboratory testing or basic scientific research are generally not regulated by the FDA when they are not intended for prevention, treatment, or diagnosis. The same principle typically applies when specimens will not be used to manufacture biologics, drugs, medical devices, or human cells, tissues, and cellular or tissue-based products.
The fact that a specimen originated in a clinical trial does not, by itself, determine FDA jurisdiction. The critical question is what will happen to the specimen after importation. Samples analyzed only to generate research data may qualify for an FDA disclaimer, while specimens used in product manufacturing, clinical diagnosis, therapeutic administration, or regulated diagnostic development may require a different analysis.
Importers should therefore document the complete use case before instructing the customs broker. Relevant questions include:
- Will test results be used to diagnose or treat an individual patient?
- Will the serum become an ingredient or component of a regulated product?
- Is the laboratory performing basic research, protocol-related analysis, or commercial diagnostic testing?
- Will the samples be cultured, propagated, pooled, transformed, or incorporated into another material?
- Are any investigational products, diagnostic systems, or manufacturing processes involved?
Descriptions such as “clinical trial samples” or “research specimens” are often too broad to support a defensible filing decision. A precise statement explaining the material, analytical purpose, and excluded uses gives the broker a stronger basis for determining whether to disclaim FDA jurisdiction or transmit FDA data.
Why FDA Product and Intended Use Codes May Be Inappropriate
A Disclaimer Is Different From an FDA Submission
When serum samples are outside FDA jurisdiction based on their intended use, the entry filer generally should disclaim FDA rather than submit an FDA Product Code. If the applicable Harmonized Tariff Schedule classification carries an FDA or other government agency flag, the filer can typically transmit the appropriate disclaimer through the Automated Commercial Environment.
Product codes such as 57DL99 and 57UL99 describe categories within the FDA-regulated blood and blood-derivative framework. They are generally intended for products that are actually subject to FDA oversight. Using one of these codes for nonregulated research specimens can mischaracterize the shipment and may trigger requests for information, admissibility review, or questions about licensing and product status.
For the same reason, FDA Intended Use Code 180.000, commonly associated with research and testing, should not be transmitted merely because the samples will be studied in a laboratory. An Intended Use Code is part of an FDA data submission. It does not replace the threshold jurisdictional determination. If the merchandise is not regulated by the FDA, transmitting a product code and Intended Use Code can create conflicting entry data where a disclaimer would have been more accurate.
Tariff classification remains a separate issue. The HTS code must be selected according to the shipment’s identity, composition, condition, and use—not simply because a particular code produces a convenient agency flag. Importers should provide sufficient technical information for classification and should avoid assuming that FDA’s product-code categories determine the proper HTS classification.
Managing CDC, CBP, and Other Import Requirements
An FDA Disclaimer Does Not End the Compliance Review
A conclusion that FDA does not regulate the samples does not mean the shipment is free from government controls. Human serum potentially containing SARS-CoV-2, influenza A, influenza B, or another infectious agent may require a CDC import permit. The permit should generally be valid for the shipment, material, origin, destination, recipient, and intended activity described in the application.
The importer and broker should also confirm that the commercial documents are consistent with the permit. Describing potentially infectious serum only as “laboratory supplies” can create an avoidable discrepancy. A more useful description identifies the material as human serum specimens, states the research or laboratory-testing purpose, and indicates the relevant infectious-agent status without making unsupported claims about safety or sterility.
A practical entry file commonly includes:
- A commercial or pro forma invoice with a specific specimen description
- The applicable CDC permit and any required permit conditions
- A research-use statement explaining that the samples are not for prevention, treatment, patient diagnosis, or regulated-product manufacturing
- The sample quantity, country of origin, consignee, and laboratory destination
- Information needed to support HTS classification and customs valuation
- Transportation records and packaging descriptions appropriate to the biological hazard classification
USDA or APHIS requirements may also apply depending on the material’s composition, processing, additives, exposure history, or associated packaging. Dangerous-goods transportation rules are another distinct workstream and may govern packaging, labeling, documentation, and carrier acceptance. These requirements should be evaluated independently rather than inferred from the FDA determination.
Customs brokers should retain the importer’s written jurisdictional rationale in the entry record. That documentation helps explain why FDA was disclaimed even though the tariff number or commodity description may attract agency attention.
- FDA guidance (reiterated on agency pages last updated around September 30–October 2, 2026) and a November 6, 2025, clarification bulletin confirm that human serum/plasma/blood specimens imported solely for clinical laboratory testing or basic scientific research—and not for prevention, treatment, diagnosis, or manufacturing of biologics, drugs, devices, or HCT/Ps—are not FDA-regulated; entry filers should disclaim FDA jurisdiction (using an HTS code with an OGA flag if possible) rather than submit an FDA Product Code.
- A CDC Etiologic Agent Import Permit remains required for these potentially infectious samples (SARS-CoV-2, influenza A/B), as noted in the same FDA materials; USDA/APHIS and CBP rules may also apply depending on the material.
- Product codes such as 57DL99 (Industry 57/CBER, Class D blood/blood components) or 57UL99 (Class U blood derivatives) are for licensed or otherwise FDA-regulated CBER products and are not appropriate here; no FDA Product Code or Intended Use Code (e.g., 180.000 research/testing) is needed if the line is properly disclaimed, though documentation should clearly state contents and research/testing-only intended use to avoid delays.
- No major new regulatory changes, import alerts, or product-code updates specific to clinical-trial serum samples appeared in the past 30 days; related 2026 FDA activity has focused on foreign clinical-trial data integrity, GCP, and restrictions on exporting U.S. patient cells rather than inbound research specimens. No relevant practitioner discussions were found on X.
Frequently Asked Questions
Are Clinical Trial Serum Samples Automatically FDA-Regulated?
No. Clinical trial origin alone generally does not establish FDA jurisdiction. The decisive factor is typically the intended use after importation. Specimens used solely for clinical laboratory testing or basic scientific research may fall outside FDA oversight when they are not used for patient diagnosis, treatment, prevention, or regulated-product manufacturing.
Should 57DL99 or 57UL99 Be Used for Research-Only Serum?
Generally, no. These FDA Product Codes correspond to regulated blood, blood components, or blood-derivative categories. Applying them to nonregulated research specimens may incorrectly represent the shipment. When the serum is outside FDA jurisdiction, the filer should generally transmit an FDA disclaimer rather than a Product Code.
Is Intended Use Code 180.000 Required for Laboratory Research?
Not when the line is properly disclaimed from FDA oversight. Intended Use Code 180.000 is part of an FDA submission and does not need to accompany an FDA disclaimer. It may be relevant only when the merchandise is FDA-regulated and the specific intended use supports that code.
Does a CDC Permit Replace FDA or CBP Entry Requirements?
No. A CDC permit addresses the importation of qualifying infectious biological agents, substances, or vectors. It does not determine FDA jurisdiction, establish the HTS classification, satisfy CBP valuation requirements, or replace accurate entry data. Each agency’s requirements must be evaluated separately.
What Documentation Can Reduce Clearance Delays?
The entry package should clearly identify the specimens, infectious-agent status, intended laboratory activity, excluded uses, consignee, and destination. It should also include the CDC permit when required. Consistency among the invoice, air waybill, permit, research statement, and broker instructions is particularly important.
How Stable Software Can Help
Supporting Broker-Led Trade Compliance
Serum imports demonstrate why customs brokers need disciplined client intake, clear filing instructions, and defensible records for agency disclaimers. Although FDA and CDC determinations remain shipment-specific, standardized workflows can help brokers identify missing information before an entry is transmitted.
Stable Software develops DrawbackAI, flat-license duty drawback software that U.S. customs brokers can white-label for importer clients and use to file under their own filer codes. Stable Software charges a flat software license and never takes a percentage of the refund. Brokers seeking to expand technology-enabled services while preserving control of client relationships and filings can learn more about Stable Software’s approach for customs brokers.
Resources
| Type | Resource |
|---|---|
| Source | Primary source |
